Skip to Main Content

Paper Details

Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Front Immunol
41
2021
BNT162b2, COVID-19, MS, Multiple Sclerosis, Nucleocapsid, Patients, SARS, SARS-CoV, SARS-CoV-2, alemtuzumab, anti-, anti-Spike (S) protein, azathioprine, dimethyl fumarate, fingolimod, glatiramer acetate, interferon, mRNA, multiple sclerosis, natalizumab, ocrelizumab, patients, rituximab, teriflunomide
Author NameAffiliation
Valeria OrrùInstitute for Genetic and Biomedical Research, National Research Council
Edoardo FiorilloInstitute for Genetic and Biomedical Research, National Research Council
Francesco CuccaInstitute for Genetic and Biomedical Research, National Research Council
Francesco CuccaUniversity of Sassari
Francesco CuccaInstitute for Genetic and Biomedical Research, National Research Council
Francesco CuccaUniversity of Sassari
  • 1 - 6

Datasets

Release 1.2